| 47041-9 |
Confirmatory consultation note |
Find |
Hospital |
Pt |
Doc |
{Role} |
|
ACTIVE |
Hospital Consultation 2nd opinion |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
47041-9 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Hosp Confirm consult note |
|
|
|
N |
|
Confirm consult note; Consult note; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; Hosp; Inpatient; notes; Point in time; Random; Visit note |
2.67 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Changed System from 'Inpatient' to 'Hospital'. Edits based on Clinical LOINC Committee approval at 1/20/2011 meeting to harmonize existing terms with Document Ontology values.; Based on Clinical LOINC Committee decision during the September 2014 meeting, {Provider} was changed to {Author Type} to emphasize a greater breadth of potential document authors. At the September 2015 Clinical LOINC Committee meeting, the Committee decided to change {Author Type} to {Role} to align with the 'Role' axis name in the LOINC Document Ontology. |
0 |
| 47042-7 |
Counseling note |
Find |
{Setting} |
Pt |
Doc |
{Role} |
|
ACTIVE |
Counseling note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
47042-7 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Counseling note |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on Clinical LOINC Committee decision during the September 2014 meeting, {Provider} was changed to {Author Type} to emphasize a greater breadth of potential document authors. At the September 2015 Clinical LOINC Committee meeting, the Committee decided to change {Author Type} to {Role} to align with the 'Role' axis name in the LOINC Document Ontology. |
0 |
| 47043-5 |
Group counseling note |
Find |
{Setting} |
Pt |
Doc |
{Role} |
|
ACTIVE |
Group counseling note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
47043-5 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Group counseling note |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.67 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on Clinical LOINC Committee decision during the September 2014 meeting, {Provider} was changed to {Author Type} to emphasize a greater breadth of potential document authors. At the September 2015 Clinical LOINC Committee meeting, the Committee decided to change {Author Type} to {Role} to align with the 'Role' axis name in the LOINC Document Ontology. |
0 |
| 47044-3 |
Initial evaluation note |
Find |
Hospital |
Pt |
Doc |
{Role} |
|
ACTIVE |
Hospital Initial evaluation note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
47044-3 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Hosp Initial eval note |
|
|
|
N |
|
Assessment; DOC.ONT; Document; Encounter; Eval; Eval note; Evaluation and management; Evaluation and management note; Finding; Findings; H&P; History and physical; Hosp; Initial eval note; Inpatient; notes; Point in time; Random; Visit note |
2.67 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Changed System from 'Inpatient' to 'Hospital'. Edits based on Clinical LOINC Committee approval at 1/20/2011 meeting to harmonize existing terms with Document Ontology values.; Based on Clinical LOINC Committee decision during the September 2014 meeting, {Provider} was changed to {Author Type} to emphasize a greater breadth of potential document authors. At the September 2015 Clinical LOINC Committee meeting, the Committee decided to change {Author Type} to {Role} to align with the 'Role' axis name in the LOINC Document Ontology. |
0 |
| 47045-0 |
Study report |
Find |
{Setting} |
Pt |
Doc |
{Role} |
|
ACTIVE |
Study report |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.MISC |
|
47045-0 |
|
{Role} |
|
|
Observation |
|
|
|
0 |
Study report |
|
|
|
N |
|
DOC.MISC; Document; Finding; Findings; MISC; Point in time; Random; Study report |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on Clinical LOINC Committee decision during the September 2014 meeting, {Provider} was changed to {Author Type} to emphasize a greater breadth of potential document authors. At the September 2015 Clinical LOINC Committee meeting, the Committee decided to change {Author Type} to {Role} to align with the 'Role' axis name in the LOINC Document Ontology. |
0 |
| 47046-8 |
Summary of death note |
Find |
{Setting} |
Pt |
Doc |
{Role} |
|
ACTIVE |
Summary of death note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
47046-8 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Summary of death |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.67 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on Clinical LOINC Committee decision during the September 2014 meeting, {Provider} was changed to {Author Type} to emphasize a greater breadth of potential document authors. At the September 2015 Clinical LOINC Committee meeting, the Committee decided to change {Author Type} to {Role} to align with the 'Role' axis name in the LOINC Document Ontology. |
0 |
| 47047-6 |
Supervisory note |
Find |
{Setting} |
Pt |
Doc |
{Role} |
|
ACTIVE |
Supervisory note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
47047-6 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Supervisory note |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.67 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on Clinical LOINC Committee decision during the September 2014 meeting, {Provider} was changed to {Author Type} to emphasize a greater breadth of potential document authors. At the September 2015 Clinical LOINC Committee meeting, the Committee decided to change {Author Type} to {Role} to align with the 'Role' axis name in the LOINC Document Ontology. |
0 |
| 47048-4 |
Diagnostic interventional radiology study |
Find |
^Patient |
Pt |
Doc |
Interventional radiology |
|
ACTIVE |
Diagnostic interventional radiology study |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.MISC |
|
47048-4 |
|
Interventional radiology |
|
|
Observation |
|
|
|
0 |
Dx interventional study IR |
|
|
|
N |
|
DOC.MISC; Document; Dx Interv Rad stdy; Finding; Findings; IR; MISC; Point in time; Random; Study report |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Release 2.72: SYSTEM: Model fix; CLASS: Greater specification; COMPONENT: Update naming convention for studies.; |
0 |
| 47049-2 |
Communication note |
Find |
{Setting} |
Pt |
Doc |
{Non-patient} |
|
DEPRECATED |
Deprecated Non-patient Communication note |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
47049-2 |
|
{Non-patient} |
|
|
Observation |
|
|
|
0 |
Deprecated Non-patient Communication |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.5 |
2.19 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 4705-0 |
HLA-A66(10) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A66(10) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4705-0 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A66(10) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47050-0 |
Herpes virus 8 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Herpes virus 8 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47050-0 |
|
IF |
|
|
Both |
|
|
|
0 |
HHV8 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; Herpesvirus; HHV; HHV8; HHV-8; Human herpes virus; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Kaposi's Sarcoma-Associated Herpesvirus; KSHV; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47051-8 |
Treponema pallidum Ab.IgG |
ACnc |
CSF |
Pt |
Qn |
IF |
|
ACTIVE |
Treponema pallidum IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47051-8 |
|
IF |
|
|
Both |
|
|
|
0 |
T pallidum IgG CSF IF-aCnc |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; FA; Fluorescent antibody; Fluorescent treponemal antibody; Fluoresent; FTA-ABS; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Syphilis; T pallidum; Time Resolved Fluorescence; Treponemal; TRF |
2.7 |
2.19 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 47052-6 |
Chlamydophila pneumoniae Ab |
ACnc |
Ser |
Pt |
Qn |
IF |
|
ACTIVE |
Chlamydophila pneumoniae Ab [Units/volume] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
MICRO |
|
47052-6 |
|
IF |
|
|
Both |
|
|
|
0 |
C pneum Ab Ser IF-aCnc |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; C pneum; C pneumo; C pneumoniae; Chlamydia; Chlamydia pneumoniae; CPN; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Pneu; pneum; Pneumo; Pneumon; Pneumonia; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Time Resolved Fluorescence; TRF; Twar agent |
2.7 |
2.19 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 47053-4 |
Enolase.neuron specific |
MCnc |
CSF |
Pt |
Qn |
IA |
|
ACTIVE |
Enolase.neuron specific [Mass/volume] in Cerebral spinal fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHEM |
|
47053-4 |
|
IA |
|
|
Both |
|
|
|
0 |
NSE CSF IA-mCnc |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; EIA; ELFA; ELISA; ENO2; enolase 2; Enzyme immunoassay; Gamma-enolase; IAA; Level; Mass concentration; MEIA; NSE; Phosphopyruvate dehydratase; Phosphopyruvate hydratase.gamma subunit; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS; Tumor marker |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47054-2 |
Legionella pneumophila 10 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 10 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47054-2 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 10 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 10; L pneumo 10 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47055-9 |
Legionella pneumophila 11 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 11 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47055-9 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 11 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 11; L pneumo 11 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47056-7 |
Legionella pneumophila 11 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 11 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47056-7 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 11 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 11; L pneumo 11 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47057-5 |
Legionella pneumophila 12 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 12 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47057-5 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 12 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 12; L pneumo 12 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47058-3 |
Legionella pneumophila 12 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 12 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47058-3 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 12 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 12; L pneumo 12 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47059-1 |
Legionella pneumophila 13 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 13 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47059-1 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 13 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 13; L pneumo 13 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 4706-8 |
HLA-A66(10) |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A66(10) [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4706-8 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A66(10) Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47060-9 |
Legionella pneumophila 13 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 13 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47060-9 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 13 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 13; L pneumo 13 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47061-7 |
Legionella pneumophila 14 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 14 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47061-7 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 14 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 14; L pneumo 14 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47062-5 |
Legionella pneumophila 14 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Legionella pneumophila 14 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47062-5 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo 14 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 14; L pneumo 14 Ab; L pneumonphila; Legion; Legionela; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47063-3 |
Treponema pallidum Ab.IgM |
ACnc |
CSF |
Pt |
Qn |
IF |
|
ACTIVE |
Treponema pallidum IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47063-3 |
|
IF |
|
|
Both |
|
|
|
0 |
T pallidum IgM CSF IF-aCnc |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; FA; Fluorescent antibody; Fluorescent treponemal antibody; Fluoresent; FTA-ABS; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Syphilis; T pallidum; Time Resolved Fluorescence; Treponemal; TRF |
2.7 |
2.19 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
